Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (51-60 of 425) with videos related to

Pageof 43
Sort By:
American Journal of Preventive Cardiology|July 30, 2021
Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based GuidelinesPeter P Toth
Journal of the American College of Cardiology|May 30, 2020
Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds ThemPeter P Toth
American Journal of Preventive Cardiology|September 6, 2021
ASPC President's Page: Addressing Unmet Needs in Preventive CardiologyPeter P Toth
American Journal of Preventive Cardiology|May 24, 2022
ASPC president's page: Getting back to basics one patient at a timePeter P Toth
Postgraduate Medicine|June 18, 2011
Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitusPeter P Toth
Journal of Clinical Hypertension (Greenwich, Conn.)|January 11, 2011
Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapyPeter P Toth
Current Diabetes Reviews|March 21, 2012
Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarctionPeter P Toth
Circulation|April 21, 2004
High-density lipoprotein and cardiovascular riskPeter P Toth
Postgraduate Medicine|March 6, 2010
Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. CommentaryPeter P Toth
Current Atherosclerosis Reports|August 18, 2005
New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatinPeter P Toth
Pageof 43

Showing results (51-60 of 425) with videos related to

Sort By:
Pageof 43
American Journal of Preventive Cardiology|July 30, 2021
Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based GuidelinesPeter P Toth
Journal of the American College of Cardiology|May 30, 2020
Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds ThemPeter P Toth
American Journal of Preventive Cardiology|September 6, 2021
ASPC President's Page: Addressing Unmet Needs in Preventive CardiologyPeter P Toth
American Journal of Preventive Cardiology|May 24, 2022
ASPC president's page: Getting back to basics one patient at a timePeter P Toth
Postgraduate Medicine|June 18, 2011
Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitusPeter P Toth
Journal of Clinical Hypertension (Greenwich, Conn.)|January 11, 2011
Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapyPeter P Toth
Current Diabetes Reviews|March 21, 2012
Effective management of the type 2 diabetes patient with cardiovascular and renal disease: secondary prevention strategies after a myocardial infarctionPeter P Toth
Circulation|April 21, 2004
High-density lipoprotein and cardiovascular riskPeter P Toth
Postgraduate Medicine|March 6, 2010
Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. CommentaryPeter P Toth
Current Atherosclerosis Reports|August 18, 2005
New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatinPeter P Toth
Pageof 43